XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statement of Shareholders' Equity (Deficiency)
$ in Thousands
Common shares
USD ($)
shares
Common shares
TruHC Pharma GmbH [Member]
EUR (€)
shares
Additional paid-in capital
USD ($)
Accumulated other comprehensive (loss) income
USD ($)
Accumulated deficit
USD ($)
Accumulated deficit
TruHC Pharma GmbH [Member]
EUR (€)
Non-controlling interests in subsidiaries (deficiency)
USD ($)
USD ($)
shares
TruHC Pharma GmbH [Member]
EUR (€)
Balance, shares at Dec. 31, 2021 | shares 3,276                
Balance, amount at Dec. 31, 2021 $ 0   $ 116,810 $ (1,108) $ (38,536)   $ (225) $ 76,941  
December unit offering, shares | shares 625                
December unit offering, amount     5,000         5,000  
December unit offering issuance costs     (415)         $ (415)  
Share repurchase, shares | shares (18)             (18,411)  
Share repurchase, amount     (255)         $ (255)  
Common shares issued for business combinations, shares | shares 2,651                
Common shares issued for business combinations, amount     24,492         24,492  
Equity issued for other agreements, shares | shares 40                
Equity issued for other agreements, amount     1,554         1,554  
Acquisition of noncontrolling interest, shares | shares 6                
Acquisition of noncontrolling interest, amount     283   (365)   28 (54)  
Options issued     4,003         4,003  
Options exercised shares | shares 27                
Options exercised, amount     82         82  
Options forfeited     (1,580)   451     (1,129)  
Restricted stock vesting, shares | shares 146                
Restricted stock vesting, amount     446         446  
Warrants exercised, shares | shares 23                
Warrants exercised, amount     105         105  
Warrants expired/cancelled               0  
Share issuance costs     (105)         (105)  
Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)       (1,624)       (1,624)  
Foreign currency translation, tax amount               0  
Net loss         (52,415)   (214) (52,629)  
Balance, shares at Dec. 31, 2022 | shares 6,776 25,000              
Balance, amount at Dec. 31, 2022 $ 0 € 12,500 150,420 (2,732) (90,865) € (216,882) (411) 56,412 € (204,382)
Balance, shares at Feb. 17, 2022 | shares   25,000              
Balance, amount at Feb. 17, 2022 | €   € 12,500       0     12,500
Net loss | €           (216,882)     (216,882)
Balance, shares at Dec. 31, 2022 | shares 6,776 25,000              
Balance, amount at Dec. 31, 2022 $ 0 € 12,500 150,420 (2,732) (90,865) (216,882) (411) 56,412 (204,382)
Equity issued for other agreements, shares | shares 16                
Equity issued for other agreements, amount     95         95  
Options vested     119         119  
Options forfeited     (765)   765        
Restricted units granted, shares | shares 52                
Restricted units granted, amount     534         534  
Other comprehensive loss -exchange differences (net of income taxes of $nil)       357       357  
Foreign currency translation, tax amount               0  
Net loss         (3,876) (59,893) (29) (3,905) (59,893)
Balance, shares at Mar. 31, 2023 | shares 6,844 25,000              
Balance, amount at Mar. 31, 2023 $ 0 € 12,500 150,403 (2,375) (93,976) (276,775) (440) 53,612 (264,275)
Balance, shares at Dec. 31, 2022 | shares 6,776 25,000              
Balance, amount at Dec. 31, 2022 $ 0 € 12,500 150,420 (2,732) (90,865) (216,882) (411) 56,412 (204,382)
September unit offering shares | shares 1,369                
September unit offering, amount     2,738         2,738  
September unit offering issuance costs     (254)         (254)  
Equity issued for other agreements, shares | shares 126                
Equity issued for other agreements, amount     590         590  
Options issued     226         226  
Options forfeited     (5,627)   5,352     (275)  
Restricted units granted, shares | shares 838                
Restricted units granted, amount     1,989         1,989  
Restricted stock cancelled, shares | shares (174)                
Restricted stock cancelled, amount     (844)         (844)  
Share issuance costs     (145)         (145)  
Derecognition of equity related to Colombia assets       1,310     (278) 1,032  
Other comprehensive loss - exchange differences on foreign operations (net of income taxes of $nil)       1,282       1,282  
Foreign currency translation, tax amount               0  
Net loss         (57,036) (371,787) 689 (56,347) (371,787)
Balance, shares at Dec. 31, 2023 | shares 8,935 25,000              
Balance, amount at Dec. 31, 2023 $ 0 € 12,500 149,093 (140) (142,549) (588,669) 0 6,404 (576,169)
Equity issued for other agreements, shares | shares 50                
Equity issued for other agreements, amount     55         55  
Options vested     5         5  
Options forfeited     (303)   303        
Restricted stock vested     14         14  
Restricted stock cancelled, shares | shares (4)                
Restricted stock cancelled, amount     (9)         (9)  
Share issuance costs     16         (16)  
Other comprehensive loss -exchange differences (net of income taxes of $nil)       27       27  
Foreign currency translation, tax amount               0  
Contribution,Amount | €   € 12,500             12,500
Net loss         (3,374) (105,572)   (3,374) (105,572)
Balance, shares at Mar. 31, 2024 | shares 8,981 25,000              
Balance, amount at Mar. 31, 2024 $ 0 € 25,000 $ 148,871 $ (113) $ (145,620) € (694,241) $ 0 $ 3,138 € (669,241)